Revuforj
Payments companies reported to CMS as associated with Revuforj. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Revuforj, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Revuforj
These are the largest totals companies reported as associated with Revuforj. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Moshe Levy | Dallas, TX | Medical Oncology | $104,572.35 |
| James Mccloskey | Hackensack, NJ | Medical Oncology | $97,556.24 |
| Shahram Mori | Orlando, FL | Hematology & Oncology | $86,721.44 |
| Jamie Koprivnikar | Hackensack, NJ | Medical Oncology | $75,611.37 |
| Mojtaba Akhtari | Omaha, NE | Hematology & Oncology | $58,171.46 |
| Salman Fazal | Pittsburgh, PA | Hematology & Oncology | $51,845.84 |
| Mohamed Hegazi | Louisville, KY | Hematology & Oncology | $36,418.60 |
| Firas El Chaer | Miami, FL | Hematology (Internal Medicine) | $34,583.94 |
| David Sallman | Tampa, FL | Hematology & Oncology | $31,794.30 |
| George Yaghmour | Los Angeles, CA | Hematology & Oncology | $28,563.50 |
Prescribed Revuforj?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.